Castle Biosciences (CSTL) Gross Profit (2018 - 2026)

Castle Biosciences has reported Gross Profit for 9 years, with the latest figure at $79.8 million in Q2 2026.

• Quarterly Gross Profit rose 16.46% year-over-year to $79.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $276.0 million (down 1.58% YoY) and the FY2025 annual result came in at $273.2 million, changed 0.49% from the prior year.
• Gross Profit improved to $79.8 million in Q2 2026 per CSTL's latest filing, from $63.1 million in the prior quarter.
• Over five years, Gross Profit peaked at $79.8 million in Q2 2026 and troughed at $20.9 million in Q1 2022.
• A 5-year average of $53.8 million and a median of $61.1 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2023 and 2026: Gross Profit soared 86.33% in 2023, then slipped 11.81% in 2026.
• Over 5 years, Gross Profit stood at $28.8 million in 2022, then surged by 86.33% to $53.7 million in 2023, then jumped by 30.6% to $70.1 million in 2024, then retreated by 2.04% to $68.7 million in 2025, then increased by 16.23% to $79.8 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $79.8 million, $63.1 million, and $68.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.